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Abstract
Aim: We wanted to examine survival in patients with resected colorectal cancer (CRC) 
whose lung metastases are or are not resected.
Methods: Teams participating in the study of Pulmonary Metastasectomy in Colorectal 
Cancer (PulMiCC) identified potential candidates for lung metastasectomy and invited 
their consent to join Stage 1. Baseline data related to CRC and fitness for surgery were 
collected. Eligible patients were invited to consent for randomization in the PulMiCC 
randomized controlled trial (Stage 2). Sites were provided with case report forms for 
non- randomized patients to record adverse events and death at any time. They were all 
reviewed at 1 year. Baseline and survival data were analysed for the full cohort.
Results: Twenty- five clinical sites recruited 512 patients from October 2010 to January 
2017. Data collection closed in October 2020. Before analysis, 28 patients with non- CRC 
lung lesions were excluded and three had withdrawn consent leaving 481. The date of death 
was known for 292 patients, 136 were alive in 2020 and 53 at earlier time points. Baseline 
factors and 5- year survival were analysed in three strata: 128 non- randomized patients did 
not have metastasectomy; 263 had elective metastasectomy; 90 were from the randomized 
trial. The proportions of solitary metastases for electively operated and non- operated pa-
tients were 69% and 35%. Their respective 5- year survivals were 47% and 22%.
Conclusion: Survival without metastasectomy was greater than widely presumed. 
Difference in survival appeared to be largely related to selection. No inference can be 
drawn about the effect of metastasectomy on survival in this observational study.
K E Y W O R D S
lung metastasectomy, prospective observational study
What does this paper add to the literature?
The assumed near- zero survival without resection of patients with lung metastases from colorectal 
cancer was not supported by this study. It seems likely that a much smaller part of the 40% observed 
5- year survival can be attributed to lung metastasectomy than is widely believed.
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INTRODUC TION
The Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) 
study enrolled 512 patients who were being considered for lung me-
tastasectomy from October 2010 to January 2017. Nested within 
this observational study was the PulMiCC randomized controlled 
trial (RCT) of 93 patients. The RCT was reported in Colorectal Disease 
in 2020 [1]. The widely believed large survival benefit from lung me-
tastasectomy was not evident although a small late effect cannot 
be excluded. Patient- reported outcomes— quality of life and health 
utility— declined at a similar rate in the metastasectomy and the un-
operated control arms [2,3].
The PulMiCC study was run in the context of a firm belief in 
the clinical effectiveness of lung metastasectomy. In response to a 
paper arguing the case for a trial [4], the European Journal of Cardio- 
Thoracic Surgery published an Editorial in 2017 proclaiming ‘Surgery 
for pulmonary metastases is a pillar of modern thoracic surgery’ 
[5]. In support of lung metastasectomy for colorectal cancer (CRC), 
the authors cited two retrospective single- institution studies [6,7]. 
These provided a pooled 5- year survival of 60% in groups of 165 
and 113 patients collected over 10 and 12 years. The Work Force of 
Evidence Based Surgery of the Society of Thoracic Surgeons based 
its recommendations for lung metastasectomy on the assumption 
that 5- year survival without resection is zero [8]. Neither statement 
was supported by control data. These publications in the leading 
thoracic surgical journals invite the conclusion that lung metastasec-
tomy provides 60% survival benefit. This widely held belief and the 
climate of certainty resulted in multidisciplinary teams (MDTs) hav-
ing difficulty randomizing patients into the PulMiCC trial (Figure 1).
Although PulMiCC found no difference in survival, a small sur-
vival advantage due to resection of lung metastases that prove to be 
the only site of residual CRC cannot be discounted. But the trial was 
large enough to refute the improbable 0% [8] and the less extreme 
estimate of 5% more generally cited [9]. The 5- year survival in the 
control group was 30% (95% CI 15.3– 45.7%), significantly above 5% 
(P < 0.001) [1].
Colorectal Disease has recently published a big data study of pul-
monary metastasectomy for CRC [10]. Among 173 354 patients who 
had a CRC resection from 2005 to 2013, lung resection was subse-
quently reported in 3434 patients which averages 2% over the time 
span of the study. From this an average number of pulmonary me-
tastasectomy operations for CRC can be estimated at about 380 per 
annum in the National Health Service (NHS) in England. During an 
overlapping period from late 2010 to early 2017, the PulMiCC cohort 
recruited more than 300 patients who had a lung metastasectomy 
for CRC which is equivalent to about 14% of all patients having this 
procedure in England.
Here we report data from the full PulMiCC cohort. The large ma-
jority of the patients were not randomized and so we cannot draw 
any valid inferences about survival attributable to lung metastasec-
tomy. Nevertheless, the characteristics of the large sample of pa-
tients and their outcomes are available to inform the Association of 
Coloproctology of Great Britain and Ireland (ACPGBI) IMPACT initia-
tive and the design of future research in this uncertain area [11,12].
F I G U R E  1  Concerned by the low rate of randomization into the RCT the Independent Data Monitoring Committee asked for an 
investigation. The three largest recruiting centres (Bristol, Liverpool and Sheffield) provided reasons for not randomizing in 155 patients. 
Among 78 patients for whom the MDT overrode the patients' wishes to be in a controlled trial, 77 (99%) were operated on. When patients 
made their own decision they were more evenly divided, demonstrating group equipoise. The results are given in the Sankey chart. Diagram 
created using SankeyMATIC (http://sanke ymatic.com/)
Patients elected to make their own decision: 41
Clinical team overrode the trial protocol: 78
Primary lung neoplasia: 10
Registered patients: 155
Chose metastasectomy.: 22
Chose not to have metastasectomy.: 19
Metastasectomy.: 77
Other reasons: 9
Local interpretation of the trial protocol: 9
Non-operative management.: 1
Deemed ineligible: 18
Undecided at time of data collection: 8
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GENER AL METHODS
Recruitment
The PulMiCC cohort study was planned around the PulMiCC RCT. 
The study was administered by clinical trials staff based at the re-
cruiting hospitals under the direction of the site's principal investiga-
tor (PI) who was either a thoracic surgeon or an oncologist. Patients 
who were potential candidates for lung metastasectomy were given 
written information and an explanatory DVD to take home. A health-
care professional training DVD was also available for clinicians to aid 
their discussions with patients.
Interested patients were invited to sign Stage 1 to be assessed 
for lung metastasectomy within PulMiCC and to be registered by 
the trials unit. They consented to collection of baseline information: 
sex, age, height and weight to derive body mass index, the interval 
since primary CRC resection, whether they had prior liver metasta-
sectomy, the number of lung metastases, carcinoembryonic antigen 
assay (CEA) and tests of lung function.
Stage 1 consent included 1- year follow- up by a Case Report 
Form (CRF) to record treatments since evaluation, including lung 
metastasectomy and other cancer directed local interventions. The 
sites were given CRFs to report death, serious adverse events, new 
lung metastases, new liver metastases and other cancer recurrence.
The local MDT considered whether patients should have lung 
metastasectomy and, if they were uncertain, agreed to offer patients 
randomization in the PulMiCC RCT. When the PulMiCC was closed, 
in view of the size and wealth of baseline data about the 82.2% non- 
randomized patients we sought Research Ethics Committee agree-
ment to approach sites for follow- up data. Approval was readily 
granted as an audit of practice on 11 February 2019. All patients who 
gave consent on entry to Stage 1 are accounted for in this analysis.
From 11 February 2019, all the site PIs and trials staff were ap-
proached with an individualized CRF request for each patient in 
Stage 1 asking for a date of death or when last known alive. We 
repeated the requests for missing survival information until the end 
of October 2020.
Statistical methods
Data from the full PulMiCC cohort were used to investigate baseline 
factors that influenced survival. Patients not known to have died 
were censored at the last time they were known to be alive in all 
analyses of survival. These investigations were based on Cox's rela-
tive risk model with time to death as the outcome and time from co-
hort entry as the time scale. The observational nature of the cohort 
does not support the estimation of treatment effects. Three strata 
were defined and all analyses were stratified on this basis.
1. The first stratum included all patients who were not randomized 
and did not have a metastasectomy. They entered the analysis 
from their time of cohort entry.
2. Patients receiving an elective metastasectomy formed the second 
stratum, entered at the time of their operation.
3. Patients in the RCT formed the third stratum entering at the time 
of randomization.
Results are summarized as hazard ratios (HRs) with confidence 
intervals (CIs). An HR greater than 1 indicates that larger values of 
the risk factor are associated with poorer survival and an HR less 
than 1 indicates that larger values are associated with higher sur-
vival. For categorical risk factors, an HR >1 indicates that poorer 
survival is associated with the presence of the risk factor (e.g., for 
male sex) or with a risk factor category compared to the reference 
category as for performance status using the Eastern Cooperative 
Oncology Group (ECOG) scores.
For descriptive purposes, survival curves were also estimated 
based on the fixed grouping of the patients into these three strata. 
The times of origin for these three curves are different and are the 
dates of cohort entry. These classifications are retrospective and 
therefore analyses using these from the time of cohort entry are ad 
hoc because the classes are determined after cohort entry and, more 
importantly, by decisions made by the patient and MDT following 
cohort entry.
RESULTS
Sources of patients and composition of the three 
strata
In all, 512 patients were recruited into Stage 1 of the PulMiCC trial 
from October 2010 to January 2017 from 25 clinical sites, mainly in 
England but also in China, Scotland, Serbia and Sicily (Table 1). Of 
the 512 patients, 31 were excluded for reasons given in Table 2. This 
left 481 patients in the cohort, of whom 90 had been randomized 
in the PulMiCC RCT. Of these, 41 never had a metastasectomy and 
49 had a lung metastasectomy 0 to 627 days after randomization 
(median 51; interquartile range 27– 160 days) including some late 
crossovers.
We received a record of the date of death for 292 of them. Four 
patients who had metastasectomy died on the day of surgery. For 
the 189 patients without death dates, 136 were known to be alive in 
2020, 33 in 2019 and for 20 patients last alive dates were longer ago 
than the end of December 2018 (Figure 2, Table 3). Data collected 
up to October 2020 are used in this analysis. The source, mix and 
eventual outcome of the three strata are shown in Figure 3.
Mortality risk factors
The baseline risk factors for the patients in the three strata are 
shown in Table 4. The proportions of metastases in the three strata 
(Figure 4) show the predominance of solitary metastases (69%) in 
the elective metastasectomy group (Table 5).
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Table 6 presents the results from single- factor analyses of base-
line factors derived from stratified Cox regression models. The table 
includes the number of deaths examined in each analysis as these 
vary depending on the number of patients for whom information is 
available on the various potential risk factors. The factors demon-
strating evidence of a higher mortality risk were higher values of 
log(CEA), a shorter interval from CRC to cohort entry and higher 
ECOG classes with a suggestive effect for male sex. Multiple lung 
metastases and prior liver metastases also demonstrated limited 
potential for an increase in mortality so were also considered for 
multi- factor analyses. There was some evidence that the effect for 
log(CEA) was different in different strata. Estimated HRs and 95% 
CIs were 1.73 (1.37, 2.19), 1.16 (0.93, 1.44) and 1.58 (1.22, 2.05) in 
the elective no metastasectomy, elective metastasectomy and ran-
domized groups respectively with no effect being demonstrable in 
the elective metastasectomy group.
Table 7 presents results from multi- factor stratified Cox regres-
sion models including variables demonstrating some potential for a 
relationship in single- factor analyses. The set of models presented 
is based on gradually decreasing numbers of deaths depending on 
the availability of risk factor information for the variables included 
with a final model with the four most significant variables. These 
were male sex, interval (shorter) from CRC to cohort entry, prior 
liver metastases and log(CEA). Again, there was evidence of differ-
ential effects for log(CEA) with estimated HRs and 95% CIs of 1.57 
(1.20, 2.04), 1.14 (0.92, 1.43) and 1.52 (1.16, 1.98) in the elective no 
metastasectomy, elective metastasectomy and randomized groups 
respectively.
Survival
With a time origin of cohort entry, Figure 5 displays Kaplan– Meier 
estimated survival curves and 95% CIs of three groups of patients 
retrospectively classified in the strata: non- randomized and no me-
tastasectomy, elective metastasectomy, and randomized.
Figure 6 displays the estimated survival after metastasectomy 
curves for randomized and elective metastasectomy patients. The 
curve in Figure 6 begins at a value of 0.989 for elective patients 
because there were three patients with a death date on the same 
day as the day of metastasectomy. The curve for randomized pa-
tients begins at 0.980 with one death on the day of metastasectomy. 
Overall, in the 6 months after metastasectomy there were 9/288 
deaths compared with 2/166 among those who did not have an op-
eration in the 6 months after cohort entry.
Over the time period after metastasectomy, the overall estimated 
HR (95% CI) for multiple metastases vs. a single metastasis, stratified 
by elective/randomized status, in PulMICC patients having a metasta-
sectomy is 1.33 (0.94, 1.88) (P = 0.10). The separate estimates based 
on elective and randomized metastasectomies are 1.18 (0.80, 1.76) 
(P = 0.40) and 2.15 (0.93, 4.99) (P = 0.07) respectively providing sug-
gestive evidence for a much more marked effect in the randomized 
patients. The difference in survival for those having elective resection 
TA B L E  2  Reasons for exclusion
Total Stage 1 Recruitment 512
Reasons for exclusion
Non- neoplastic nodules 13






TA B L E  1  Trials sites and numbers of participants included at 
each site
Site City and institution
Participants 
enrolled
076 Sheffield, Northern General 
Hospital
101
073 Liverpool, Heart and Chest 
Hospital
88
062 Bristol, Royal Infirmary
Serbia, Institute for Lung 
Diseases of Vojvodina







028 London Guy's Hospital 22
060 Basildon, Basildon Hospital 15
065 Plymouth, Derriford Hospital 15
068 Glasgow, Golden Jubilee 
Hospital
15
071 Sutton in Ashfield, King's Mill 
Hospital
12
063 Manchester, Christie 11
067 Leicester, Glenfield Hospital 10
074 Wolverhampton, New Cross 
Hospital
9
105 Zhengzhou, Henan Cancer 
Hospital
6
066 Newcastle, Royal Victoria 
Hospital
5
075 Norwich, Norfolk and Norwich 
Hospital
5
080 Catania, Policlinico Hospital 5
082 London, Royal Brompton 
Hospital





069 Birmingham, Heartlands 
Hospital
2
084 London, St George's Hospital 2
072 Leeds, St James' Hospital 1
081 Burton, New Cross Hospital 1
Total patients 512
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F I G U R E  2  For 189 patients where a 
death form had not been returned this 
chart gives the date at which they were 
last known to be alive in order from the 
earliest to the most recent. Requests 
continued until October 2020 when 
we closed the study for analysis. Some 
centres regarded the close of the RCT as 
the end of their commitment to give time 
to the PulMiCC study
0 20












Sequential entries of last alive date for 189 patients
140 160 180 200
Status From To Number
Known dates of death 31 July 2012 11 August 2020 292
Known to be alive to 2020 01 January 2020 29 October 2020 136
Known to be alive to 2019 03 January 2019 30 December 2019 33
Last known to be alive 
<2019
22 October 2014 10 December 2018 20
Total 481
TA B L E  3  Recorded date of alive or 
dead status in all 481 cohort patients
F I G U R E  3  The total 512 Stage 
1 enrolled patients divide into 93 in 
the RCT and the remaining 419 in the 
observational study. After 31 exclusions 
for the reasons given in Table 2, 481 
patients from the PulMiCC cohort 
are analysed in three strata: elective 
non- metastasectomy 128, elective 
metastasectomy 263 and the 90 patients 
who were randomized. Diagram created 
using SankeyMATIC (http://sanke ymatic.
com/)
Cohort: 419
Elective M’my stratum: 263
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TA B L E  4  Data availability and median, full range and quartile values in the three strata
Data 
availablea  Percentage Minimum 0.25 Median 0.75 Maximum
Age in years
Elective no metastasectomy 128 99.2 42.4 65.7 71.9 77.7 87.9
Elective metastasectomy 263 100.0 30.8 60.0 67.0 72.8 85.6
Randomized 90 100.0 35.3 59.8 67.1 73.8 86.5
Body mass index
Elective no metastasectomy 105 81.4 17.9 25.0 27.8 30.9 57.8
Elective metastasectomy 259 98.5 17.0 24.6 27.7 31.4 56.8
Randomized 86 95.6 18.7 26.1 28.6 31.7 40.9
Carcinoembryonic antigen, ng/l
Elective no metastasectomy 82 63.6 0.3 1.7 3.0 5.9 57.0
Elective metastasectomy 144 54.8 0.3 1.3 2.0 4.0 151.0
Randomized 78 86.7 0.3 1.9 3.0 4.6 74.0
Forced expiratory volume, % predicted
Elective no metastasectomy 90 70.3 44.0 76.0 86.6 101.5 145.0
Elective metastasectomy 233 88.6 26.0 82.3 96.0 111.0 153.0
Randomized 84 93.3 46.0 78.0 93.1 109.3 139.0
Months from primary CRC resection to metastasectomy or registration
Elective no metastasectomy 117 91.4 1.3 13.9 25.6 49.7 145.4
Elective metastasectomy 253 96.2 0.0 14.3 24.7 37.1 138.7
Randomized 84 93.3 0.8 13.8 25.6 36.9 130.3
Number of metastases
Elective no metastasectomy 107 82.9 1 1 2 3 17
Elective metastasectomy 245 93.2 1 1 1 2 8
Randomized 90 100.0 1 1 2 3 9
% solitary Missing Solitary Multiple % solitary
Elective no metastasectomy 107 83.6 22 38 69 35.5%
Elective metastasectomy 245 93.2 18 169 76 69.0%
Randomized 90 100.0 0 30 60 33.3%
ECOG Missing 0 1 2
Elective no metastasectomy 90 70.3 29.7% 35.9% 29.7% 4.7%
Elective metastasectomy 215 81.7 18.3% 67.9% 31.6% 0.5%
Randomized 74 82.2 21.6% 73.0% 25.7% 1.4%
Sex Women Men % women
Elective no metastasectomy 128 100.0 42 87 36.4%
Elective metastasectomy 263 100.0 100 163 38.0%
Randomized 90 100.0 34 56 37.8%
Prior liver metastasectomy Yes No % previous
Elective no metastasectomy 121 94.5 44 77 36.4%
Elective metastasectomy 256 97.3 71 185 27.7%
Randomized 83 92.2 26 57 31.3%
Abbreviations: CEA, carcinoembryonic antigen; CRC, colorectal cancer; ECOG, Eastern Cooperative Oncology Group.
aThere are usually more missing data in the elective non- metastasectomy group because, if metastasectomy is decided against for any reason, 
other investigations may serve no purpose. CEA is an exception. It was required for minimization but the value was not always in the record. It is a 
paradoxical marker because its elevation on screening may prompt a search for metastases but its elevation is a negative predictor for survival after 
metastasectomy and may contribute to a decision against operating.
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of solitary and multiple metastases is shown in Figure 7. The number 
of lung metastases is a risk factor of particular relevance for metasta-
sectomy patients and is considered further in the next section.
Interpretation of results
All the curves in Figure 5 show a relatively slow rate of decline ini-
tially. This is a hallmark of many cancer survival studies— whether 
randomized or observational— in contrast to cancer registry data pres-
entations when there is characteristically an early sharp fall which be-
comes progressively flatter. For randomized patients, the plateau may 
be because patients have to have a good probability of short- term sur-
vival (1– 2 years) often defined by entry criteria. This is also seen among 
patients in whom the decision is individualized. All patients in the co-
hort were being considered for lung metastasectomy and therefore 
had favourable features. This provides for a further bias in addition to 
the selection of patients on prognostic features. The median interval 
F I G U R E  4  Three numbers of lung 
metastases in the three strata based on 
available data as in Table 5: (1) N = 128 
non- randomized patients who did not 
have a metastasectomy; (2) N = 263 
non- randomized patients who had a 














Solitary Two Thee Four Five Polymetastatic
3
TA B L E  5  Numbers of patients with a solitary metastasis and 2, 3, 4, 5 and polymetastatic disease in each stratum
Solitary Two Three Four Five Polymetastatic Available
Elective no metastasectomy 38 33 16 8 1 11 107/128
Elective metastasectomy 169 44 18 10 2 2 245/263
Randomized 30 31 16 4 4 5 90/90
Variable Categories
No. of 
deaths HR (95% CI) P value
Age (continuous) 292 1.00 (0.99,1.01) 0.73
Male sex 292 1.24 (0.98,1.58) 0.08
Log(CEA) 200 1.42 (1.25,1.62)a  <0.001
Liver metastasectomy (Y/N) 280 1.22 (0.95,1.56) 0.12
No. of lung 
metastasectomies > 1
265 1.19 (0.92,1.54) 0.181
Interval CRC to start (years) 274 0.90 (0.84,0.97) 0.003
BMI 269 1.00 (0.98,1.02) 0.99
ECOG 0 219 1.00
1 1.28 (0.97,1.69) 0.09
2 1.11 (0.49,2.56) 0.80
%FEV 247 1.00 (0.99,1.00) 0.20
Note: Strata: elective no metastasectomy or randomization; elective metastasectomy; randomized.
Abbreviations: BMI, body mass index; CEA, carcinoembryonic antigen; CRC, colorectal cancer; 
ECOG, Eastern Cooperative Oncology Group; FEV, forced expiratory volume in the 1st second; 
HR, hazard ratio.
aSome evidence of effects being different in different strata.
TA B L E  6  Results from single- factor 
analyses using a stratified Cox regression 
model
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from registration to elective metastasectomy was 21 days with the 
upper quartile of delayed decisions ranging from 39 to 431 days. Lung 
metastasectomy is used highly selectively, not undertaken for immi-
nently life- threatening disease. The time needed to check that there 
are no further metastases or disease at other sites allows for a further 
manifestation of selection bias seen in the initial parts of the curves 
in Figure 5B,C. This effect carries over to the initial period after the 
metastasectomy as seen by the initial plateaus in Figure 6 after deaths 
on the day of operation. We suggest that this is a form of guarantee- 
time bias [13]. It can occur when survival is timed from enrolment, and 
is compared across groups defined by a classifying event occurring 
sometime during the subsequent passage of time. In this case, patients 
who show other sites of disease, or other adverse features, fall outside 
the standard criteria for metastasectomy [14]. But metastasectomy 
remains an option for patients whose progression trajectory indicates 
the likelihood of longer survival. It is carried out if survival appears 
to be ‘guaranteed’ for a reasonable length of time. In assessment for 
liver metastasectomy there is a period of assessment before the final 
decision is made. It is a conscious policy referred to by liver surgeons 
as the ‘test of time’ [15,16].
The early deaths in the elective metastasectomy stratum merit 
attention. There were three deaths on the day of surgery and a fur-
ther five in the 6 months after operation. Although lung metastasec-
tomy is comparatively low risk, thoracic surgery is associated with 
non- trivial rates of pneumothorax, persistent air leak, bleeding, lung 
infection and pleural space infection, all of which take their toll on 
wellbeing and may contribute to deterioration and earlier death than 
would otherwise have been the case. Deaths in the months after 
operation for selected patients with very limited CRC are probably 
related to surgery. A similar inference was drawn in the analysis of 
deaths within 90 days after primary resection in the National Bowel 
Cancer Audit [17].
The relatively low hazard ratio of 1.19 for multiple vs. single 
metastases in Table 6 is not directly comparable with results de-
rived only from metastasectomy patients. In the meta- analysis of 
24 reports including 2589 patients already referred to, the hazard 
ratio for multiple vs. solitary metastases, for patients having a me-
tastasectomy, was 2.04 [9]. The better survival of patients with a 
solitary metastasis has been found repeatedly in case series, in the 
International Registry of Lung Metastases [18] and in systematic re-
views [19,20]. Figure 4 shows that among patients selected for the 
elective metastasectomy stratum the solitary metastasis rate was 
nearly double that in the unoperated patients (69% vs. 35%). A large 
difference was seen in survival after 2 years among patients with a 
difference in this risk factor.
The analysis of the randomized stratum in PulMICC produced an 
HR of 2.15 which is comparable with that in the meta- analysis, while 
there was no evidence of an effect in the elective metastasectomy 
patients. A likely explanation is that in more recent practice, aware 
of the hazard of multiple metastases, the MDT will only recommend 
metastasectomy if the balance of other risk factors is favourable. In 
randomized patients, minimization prevents trading off risk factors.
However, erosion of the effect of a risk factor as the practice be-
comes more selective has been observed in the use of risk factors in 
case selection [21]. A simple analogy might help explain. Looking at 
performance data of a large pool of high school basketball players an 
analyst noted that youths ≥2 m tall were higher scorers. They were 
preferentially picked for the county team. When the analysis was 
run for elite teams, height was no longer such a strong discriminator. 
They were nearly all very tall. Blackstone and Lauer have called this 
effect ‘work up bias’ [22]. The coach, however, continued to select 
for the squad one or two players ≥1.7 m tall who could almost unerr-
ingly shoot and score from 15 to 20 m away. As does the coach, an 
MDT looks at all the factors. If a patient has two to three metastases 
TA B L E  7  Results from multi- factor analyses using a stratified Cox regression model
Model A Model B Model C Model D Model E
No. deaths 274 270 251 191 192
Male sex 1.30 (1.02, 1.67) 
(P = 0.036)
1.29 (1.00, 1.65) (P = 
0.051)
1.20 (0.93, 1.55) (P = 
0.167)
1.25 (0.93, 1.69) (P = 
0.144)




0.90 (0.84, 0.96) 
(P = 0.002)
0.88 (0.81, 0.94) (P < 
0.001)
0.89 (0.82, 0.95) (P < 
0.001)
0.86 (0.79, 0.94) (P < 
0.001)




1.33 (1.02, 1.74) (P = 
0.035)
1.27 (0.96, 1.67) (P = 
0.092)
1.23 (0.89, 1.70) (P = 
0.210)
1.29 (0.94, 1.76) 
(P = 0.113)
No. of lung 
metastasectomies >1
1.19 (0.91, 1.55) (P = 
0.208)
1.23 (0.90, 1.68) (P = 
0.191)
ECOG (0) 1.00
ECOG (1) 1.31 (0.97, 1.78) (P = 
0.081)
ECOG (2) 0.96 (0.38, 2.44) (P = 
0.938)
Log(CEA) 1.35 (1.17, 1.55) 
(P < 0.001)
Note: Strata: elective no metastasectomy or randomization; elective metastasectomy; randomized. HR (95% CI) (P value).
Abbreviations: CEA, carcinoembryonic antigen; CRC, colorectal cancer; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio.
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that have remained much the same over a year of observation, they 
know that patient is likely to have a longer survival.
DISCUSSION
The major limitation of the PulMiCC cohort study is that it is not a 
randomized comparison and cannot provide evidence about survival 
benefit attributable to metastasectomy. The best currently available 
data are in the PulMiCC RCT report [1].
We can confidently state that the 5- year survival of people with 
lung metastases from CRC is not zero. Among 481 patients in the 
cohort, 169 patients did not have a metastasectomy and 37 of them 
were 5- year survivors (22%, 95% CI 16%– 29%). It is possible but very 
unlikely that a few of these survivors did not in fact have malignant 
lung lesions. We specifically sought information on long survivors, 
however treated, and the PIs did not report any case in whom the 
diagnosis of CRC had been wrong.
In most cases after lung metastasectomy CRC recurs sooner or 
later, but it is quite feasible that in some cases the lung metastases 
are the only residual site of disease and metastasectomy is curative. 
We hear anecdotal accounts [23] but documented proof of disease- 
free survival at a long interval after lung metastasectomy are yet 
to be seen. Reported long- term survivors have usually also had sys-
temic treatments. The majority of patients in this cohort with and 
without metastasectomy had systemic treatments. An analysis of 
those treatments is the subject of a further report.
The big data study in the English NHS already referred to 
showed that lung metastasectomy is highly selective, being used on 
only 2.3% of patients with resected CRC in 2013 [10]. A study in 
the Korean National Health Insurance Database of 2573 CRC lung 
metastasectomy patients found a similar rate of 2.5% [24]. The lung 
metastasectomy operations referred to as ‘a pillar of modern tho-
racic surgery’ were performed at a rate of about one a month in the 
two series cited in support [5]— more a flying buttress than a pillar. 
This is a highly selective practice.
F I G U R E  5  Survival in three strata with 95% confidence 
intervals. The curves are displayed separately because the entry 
points into the analyses and the baseline prognostic factors of 
those in the three strata are different. No direct comparison of 


















































































F I G U R E  6  Survival curves for all 312 patients who had 
pulmonary metastasectomy separated into those in the 
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F I G U R E  7  Survival for elective metastasectomy patients with 
solitary or multiple metastases. The difference in survival does 
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At this point, discussants of observational studies tend to point 
to ‘the need for trials’. In this instance we refer to the PulMiCC RCT, 
a trial already done. It refutes the zero assumption and substantially 
narrows the plausible effect size from the assumed 40% difference.
The National Institute for Health and Care Excellence (NICE) has 
considered the question of lung metastasectomies and the recom-
mendation was to ‘consider’ metastasectomy. While it might have 
been intended as a weak recommendation, it sends out a signal for 
‘business as usual’. The guideline development group advising NICE 
discounted PulMiCC as too small [25]. Instead, they chose to use a 
non- randomized follow- up study in which 48 had metastasectomy. 
PulMiCC's metastasectomy arm fell short of their unspecified cut- 
off with only 46 patients but there was a control group. Also rec-
ommended for consideration was peritoneal surgery. They cited an 
RCT in support. It had the same surgery in both arms but the authors 
concluded ‘that high- quality surgery is of value’ which cannot be 
derived from the abstract cited. The position with respect to liver 
resection was summed up by surgeons at Memorial Sloan Kettering: 
‘We took as our point of departure the assumption that there will 
never be an RCT to answer the question of if liver resection has a 
role in the management of CRLM [colorectal liver metastases], or 
even to quantify its exact benefits’ [26] It seems questionable that 
the practitioners of a particular form of surgery should seek to bar 
the way to its evaluation. We are aware that the IMPACT initiative 
of ACPGBI includes active detection of metastases for resection but 
meta- analysis of the many trials of more vs. less intensive screening 
protocols have found no overall survival benefit [27,28].
Thoracic surgeons have addressed the question of the clinical effec-
tiveness of lung metastasectomy by participating in the PulMiCC stud-
ies, the RCT and this cohort, but resolution of this matter is unlikely to 
come from specialist thoracic surgeons engaged in a very small part of 
the overall treatment of advanced CRC. ACPGBI have made a commit-
ment to improving the care of patients with advanced CRC [11]. That 
should include reducing and avoiding the use of ineffective treatments if 
only to make room in the budget for adopting new ones. It is noteworthy 
that, in the process of prioritizing patients for cancer treatments during 
the COVID- 19 pandemic, metastasectomy was deemed low priority. 
The use of stereotactic radiotherapy to treat ‘oligometastases’ has been 
commissioned by NHS England on the basis of very weak evidence, and 
this may well supersede the use of surgical metastasectomy [29].
Colorectal MDTs are in the best position to implement trials of 
treatments for advanced CRC. Commenting on yet another round 
of the homoeopathy vs. allopathy debate The Lancet recognized that 
allopathy might have RCT evidence but homoeopathy has a follow-
ing and while ‘doctors need to be bold and honest with their patients 
about homoeopathy's lack of benefit’ they should also be honest 
‘with themselves about the failings of modern medicine to address 
patients' needs for personalized care’. The IMPACT initiative seeks 
to personalize care [11] but all systemic treatments have been in-
troduced on the basis of controlled trial evidence. To paraphrase 
The Lancet, doctors need to be bold and honest with themselves 
about the failure to even seek proof of the effectiveness of local 
treatments. This is a declared research priority of the ACPGBI [12].
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